Acteoside inhibits human promyelocytic HL-60 leukemia cell proliferation via inducing cell cycle arrest at G0/G1 phase and differentiation into monocyte

Carcinogenesis

Volumn 28, Issue 9, 2007, Pages 1928-1936

  Lee, Kyung Won ^a   Kim, Hyoung Ja ^b   Lee, Yong Sup ^a   Park, Hee Jun ^c   Choi, Jong Won ^d   Ha, Joohun ^e   Lee, Kyung Tae ^e  

^a Kyung Hee University   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

^c Sangji University   (South Korea)

^d Kyungsung University   (South Korea)

^e Kyung Hee University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACTEOSIDE; CD14 ANTIGEN; CYCLIN D2; CYCLIN D3; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; MESSENGER RNA; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F1;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL STRAIN HL 60; CONTROLLED STUDY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MITOSIS INHIBITION; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN BINDING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL CYCLE; CELL DIFFERENTIATION; CELL DIVISION; EPIDERMAL GROWTH FACTOR; G0 PHASE; G1 PHASE; GLUCOSIDES; HL-60 CELLS; HUMANS; MUSCLE CELLS; PHENOLS; STILBENES; TETRADECANOYLPHORBOL ACETATE;

EID: 34848885483     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm126     Document Type: Article

References (53)

1. Tomas,B.J. (2005) Cell-cycle control during development: Taking it up a notch. Dev. Cell, 8, 451-452.
2. 1 phase of the cell cycle: GD. Proc. Natl Acad. Sci. USA, 79, 845-849.
3. Collins,K. et al. (1997) The cell cycle and cancer. Proc. Natl Acad. Sci. USA, 94, 2776-2778.
4. Buolamwini,J.K. (2000) Cell cycle molecular targets in novel anticancer drug discovery. Curr. Pharm. Des., 6, 379-392.
5. Hajduch,M. et al. (1999) Synthetic cyclin dependent kinase inhibitors. New generation of potent anti-cancer drugs. Adv. Exp. Med. Biol., 457, 341-353.
6. Viallard,J.F. et al. (2001) Molecular mechanisms controlling the cell cycle: Fundamental aspects and implications for oncology. Cancer Radiother., 5, 109-129.
7. Sharma,H.W. et al. (1995) Differentiation of immortal cells inhibits telomerase activity. Proc. Natl Acad. Sci. USA, 92, 12343-12346.
8. Fisher,R.P. et al. (1994) A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase. Cell, 78, 713-724.
9. Harper,J.W. et al. (1996) CDK inhibitors in development and cancer. Curr. Opin. Genet. Dev., 6, 56-64.
10. 1-phase progression. Genes Dev., 13, 1501-1512.
11. 1 phase progression: Cycling on cue. Cell, 79, 551-555.
12. Drexler,H.G. et al. (1995) Leukemia cell lines: In vitro models for the study of acute promyelocytic leukemia. Leuk. Res., 19 681-691.
13. Andersson,G. et al. (1996) Adhesion of human myelomonocytic (HL-60) cells induced by 1,25-dihydroxyvitamin D3 and phorbol myristate acetate is dependent on osteopontin synthesis and the alpha v beta 3 integrin. Connect. Tissue Res., 35, 163-171.
14. Jacobsen,S.E. et al. (1994) The growth response of Lin-Thy-1 hematopoietic progenitors to cytokines is determined by the balance between synergy of multiple stimulators and negative cooperation of multiple inhibitors. Exp. Hematol., 22, 985-989.
15. Drexler,H.G. et al. (1998) Growth-inhibitory effects of transforming growth factor-beta 1 on myeloid leukemia cell lines. Leuk. Res., 22, 927-938.
16. De Benedetti,F. et al. (1990) Synergy between transforming growth factor-beta and tumor necrosis factor-alpha in the induction of monocytic differentiation of human leukemic cell lines. Blood, 75, 626-632.
17. Selvakumaran,M. et al. (1994) Progression of the myeloid differentiation program is dominant to transforming growth factor-beta 1-induced apoptosis in M1 myeloid leukemic cells. Blood, 84, 1036-1042.
18. Defacque,H. et al. (1999) Transforming growth factor-beta1 is an autocrine mediator of U937 cell growth arrest and differentiation induced by vitamin D3 and retinoids. J. Cell. Physiol., 178, 109-119.
19. 3, all trans retinoic acid, rTGF-beta2 and their combinations. J. Steroid Biochem. Mol. Biol., 60, 87-97.
20. Ismailoglu,U.B. et al. (2002) Effects of phenylpropanoid and iridoid glycosides on free radical-induced impairment of endothelium-dependent relaxation in rat aortic rings. J. Ethnopharmacol., 79, 193-197.
21. Pu,X. et al. (2003) Acteoside from Cistanche salsa inhibits apoptosis by 1-methyl-4-phenylpyndinium ion in cerebellar granule neurons. Planta Med., 69, 65-66.
22. Xiong,Q. et al. (1996) Antioxidative effects of phenylethanoids from Cistanche deserticola. Biol. Pharm. Bull., 19, 1580-1585.
23. Wong,I.Y. et al. (2001) Antioxidative activities of phenylethanoid glycosides from Ligustrum purpurascens. J. Agri. Food Chem., 49 3113-3119.
24. Xiong,Q. et al. (2000) Inhibition of nitric oxide by phenylethanoids in activated macrophages. Eur. J. Pharmacol., 400, 137-144.
25. Lee,J.Y. et al. (2005) Inhibition of lipopolysaccharide-inducible nitric oxide synthase expression by acteoside through blocking of AP-1 activation. J. Ethnopharmacol., 97, 561-566.
26. Saracoglu,I. et al. (1995) Studies on constituents with cytotoxic and cytostatic activity of two Turkish medicinal plants Phlomis armeniaca and Scutellaria salviifolia. Biol. Pharm. Bull., 18, 1396-1400.
27. Kunvari,M. et al. (1999) Biological activity and structure of antitumor compounds from Plantago media L. Acta Pharm. Hung. 69, 232-239.
28. Ohno,T. et al. (2002) Antimetastatic activity of acteoside, a phenylethanoid glycoside. Biol. Pharm. Bull., 25, 666-668.
29. Kim,H.J. et al. (2001) HIV-1 integrase inhibitory phenylpropanoid glycosides from Clerodendron trichotomum. Arch. Pharm. Res., 24 286-291.
30. Kim,H.J. et al. (2002) HIV gp41 binding phenolic components from Fraxinus sieboldiana var. angustata. Planta Med., 68, 1034-1036.
31. Seo,B.R. et al. (2004) Saucernetin-7 isolated from Saururus chinensis inhibits proliferation of human promyelocytic HL-60 leukemia cells via G0/G1 phase arrest and induction of differentiation. Carcinogenesis, 25, 1387-1394.
32. Sherr,C.J. (2000) The Pezcoller lecture: Cancer cell cycles revisited. Cancer Res., 60, 3689-3695.
33. Elledge,S.J. et al. (1994) CDK inhibitors: On the threshold of checkpoints and development. Curr. Opin. Cell Biol., 6, 847-852.
34. Hauck,L. et al. (2005) E2F transcription factors and pRb pocket proteins in cell cycle progression. Methods Mol. Biol., 296, 239-245.
35. Zhang,F. et al. (2002) In vitro modulation of telomerase activity, telomere length and cell cycle in MKN45 cells by verbascoside. Planta Med., 68, 115-118.
36. Wartenberg,M. et al. (2003) Inhibition of tumor-induced angiogenesis and matrix-metalloproteinase expression in confrontation cultures of embryoid bodies and tumor spheroids by plant ingredients used in traditional chinese medicine. Lab. Invest., 83, 87-98.
37. Chiou,W.F. et al. (2004) Acteoside protects endothelial cells against free radical-induced oxidative stress. J. Pharm. Pharmacol. 56, 743-748.
38. Li,Y.M. et al. (2000) Fast repairing of oxidized OH radical adducts of dAMP and dGMP by phenylpropanoid glycosides from Scrophularia ningpoensis Hemsl. Acta Pharmacol. Sin., 21, 1125-1128.
39. Grana,X. et al. (1995) Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene, 11, 211-219.
40. Morgan,D.O. (1995) Principles of CDK regulation. Nature, 374 131-134.
41. Hunter,T. et al. (1994) Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell, 79, 573-582.
42. Miura,D. et al. (1999) Antagonistic action of novel 1α,25-dihydroxyvitamin D3-26,23-lactone analogs on differentiation of human leukemia cells (HL-60) induced by 1α,25-dihydroxyvitamin D3. J. Biol. Chem., 274, 16392-16399.
43. Derynck,R. et al. (2001) TGF-β signaling in tumor suppression and cancer progression. Nat. Genet., 29, 117-129.
44. Shi,Y. et al. (2003) Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell, 113, 685-700.
45. Siegel,P.M. et al. (2003) Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat. Rev. Cancer, 3, 807-821.
46. WAF1/CIP1 protein and inhibits CDK2 kinase activity in human colon carcinoma FET cells. Cancer Res., 63 3340-3346.
47. Li,F. et al. (2005) TGF-β signaling in colon cancer cells. World J. Surg., 29, 306-311.
48. Bestilny,L.J. et al. (1996) Selective inhibition of telomerase activity during terminal differentiation of immortal cell lines. Cancer Res., 56, 3796-3802.
49. Reichman,T.W. et al. (1997) Downregulation of telomerase activity in HL60 cells by differentiating agents is accompanied by increased expression of telomerase-associated protein. J. Cell. Biochem., 67, 13-23.
50. Rama,S. et al. (2003) TGF-β1 induces multiple independent signals to regulate human trophoblastic differentiation: Mechanistic insights. Mol. Cell. Endocrinol., 206, 123-136.
51. Newbold,R.F. (2002) The significance of telomerase activation and cellular immortalization in human cancer. Mutagenesis, 17, 539-550.
52. Zeng,X.L. et al. (2003) In vitro induction of differentiation by ginsenoside Rh2 in SMMC-7721 hepatocarcinoma cell line. Pharmacol. Toxicol., 93, 275-283.
53. Tauchi,T. et al. (2003) Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: Involvement of ATM-dependent DNA damage response pathways. Oncogene, 22, 5338-5347.